![Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study - The Lancet Haematology Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study - The Lancet Haematology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0d856b42-2371-4538-9dc7-f2d902430626/gr2_lrg.jpg)
Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study - The Lancet Haematology
![A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells | Nature Genetics A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells | Nature Genetics](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41588-022-01105-z/MediaObjects/41588_2022_1105_Fig1_HTML.png)
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells | Nature Genetics
![Il cancro si cura anche con il 5x1000. Airc, prima in classifica nel 2021, finanzia oggi 400 studi - la Repubblica Il cancro si cura anche con il 5x1000. Airc, prima in classifica nel 2021, finanzia oggi 400 studi - la Repubblica](https://www.repstatic.it/content/nazionale/img/2022/06/21/021839756-749253fa-0ef1-4204-b0d6-9ccbfe0320f4.jpg)
Il cancro si cura anche con il 5x1000. Airc, prima in classifica nel 2021, finanzia oggi 400 studi - la Repubblica
![5x1000 IEO: Ricerca sanitaria per tumori - Istituto Europeo Oncologia - Istituto Europeo di Oncologia 5x1000 IEO: Ricerca sanitaria per tumori - Istituto Europeo Oncologia - Istituto Europeo di Oncologia](https://www.ieo.it/PageFiles/9589/banner%20blu%20cancro%202022.png)
5x1000 IEO: Ricerca sanitaria per tumori - Istituto Europeo Oncologia - Istituto Europeo di Oncologia
![Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages | Nature Communications Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-29960-8/MediaObjects/41467_2022_29960_Fig1_HTML.png)
Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages | Nature Communications
AIRC - Fondazione AIRC per la Ricerca sul Cancro - Scegli anche tu di dire "Contro il cancro, io ci sono!" e moltiplica le speranze di chi lotta contro la malattia. Il #
![PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer | npj Breast Cancer PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-022-00382-5/MediaObjects/41523_2022_382_Fig1_HTML.png)
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer | npj Breast Cancer
![assomiglia rivista Dottore in Filosofia 5 per mille ricerca contro i tumori Morto nel mondo patrono sollevamento assomiglia rivista Dottore in Filosofia 5 per mille ricerca contro i tumori Morto nel mondo patrono sollevamento](https://www.ieo.it/Documents/5x1000/img/cancro-pauraIEO.jpg)